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Introduction
Speculation that nonsteroidal anti-inflammatory drugs
(NSAIDS) may act to decrease the risk of breast cancer
has been growing over recent years and prospective
results from the Women’s Health Initiative have provided
further confirmation of this hypothesis [1]. This risk
reduction has never previously been linked to oestrogen
(ER) or progesterone (PR) receptor status, however, a
recent population-based case control study [2] has
demonstrated an inverse relationship between aspirin use
and breast cancer in hormone receptor positive tumours.
COX and prostaglandins
NSAIDS (e.g. aspirin, ibuprofen, diclofenac) inhibit the
enzyme cyclooxygenase (COX). There are two isoforms of
COX: COX-1, which is produced in most tissues and
COX-2, which can be induced by proinflammatory stimuli,
tumour promoters and hormones. Both isoforms are
blocked by NSAIDS. COX-2 is the rate-limiting step in the
synthesis of prostaglandins and therefore NSAIDS inhibit
the production of prostaglandins, giving rise to their anti-
inflammatory, antipyretic and analgesic properties. Inhibi-
tion of prostaglandins can also decrease mutagenesis,
mitogenesis, angiogenesis and metastasis and increase
cellular apoptosis and the antineoplastic activities of T and
B lymphocytes [3].
Oestrogen synthesis is catalysed by the enzyme
aromatase cytochrome P450. Experiments in cultured
cells have shown that prostaglandin E2 increases
aromatase gene expression and thus increases oestrogen
synthesis [4]. A recent meta-analysis of results from
different trials demonstrated that NSAID use leads to a
22% reduction in the risk of developing breast cancer [5],
but in the light of the knowledge of the above pathways it
follows that this reduction should be greatest in women
who are ER positive.
Aspirin reduces the risk of ER positive
tumours
The Women’s Health Initiative is an ongoing multicentre
observational cohort study, designed to address the
causes of morbidity and mortality in postmenopausal
women. It reported a 21% reduction in breast cancer risk
in women regularly taking NSAIDS. No change in the risk
of developing breast cancer was evident in those patients
taking acetaminophen (paracetamol, an analgesia with no
anti-inflammatory properties) (n = 80,741) [1].
In the recent study [2], Terry and colleagues, designed a
population based case control study in which they
assessed 1508 patients with breast cancer and 1556
control patients. Known breast cancer risk factors were
assessed (including parity, breast feeding, family history)
along with an assessment of NSAID intake. Patients were
categorised as having ever taken aspirin/ibuprofen if they
had taken either drug at least once a week for at least a
six-month period. As the questionnaire required patients to
give information retrospectively there is the possibility of
inaccuracies in the recall of NSAID intake. A medical
history was detailed for each participant but details on the
medical indication for NSAID intake have not been
published. Intake of acetaminophen (paracetamol) was
also assessed. The ER/PR status was obtained from
pathology reports.
Previous use of aspirin was found to be inversely
associated with breast cancer risk (OR 0.8; 95% CI
0.66–0.97). The risk reduction was statistically significant
for breast cancer but a trend in reduction was also
observed in patients with in situ disease. Both pre- and
postmenopausal women showed a reduction in risk,
although it was more marked in the postmenopausal
group. With respect to hormone receptor status, the risk
reduction was seen in all subgroups (ER+ PR+, ER+
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PR–, ER– PR+) except those patients who were both ER
and PR negative. In these patients, NSAID intake bore no
correlation to breast cancer risk.
In postmenopausal women taking ibuprofen, a trend
towards a decrease in breast cancer risk was seen,
however, this was not statistically significant. There was
no association evident between breast cancer risk and
acetaminophen intake. Dose of NSAID was not assessed
but the frequency and duration of use was; patients
reporting daily use for up to 5 years showed the greatest
risk reduction. As COX is continuously synthesised it
follows logically that regular intake of NSAID will be
necessary to effectively reduce prostaglandin production –
with the drawback of an increased risk of gastrotoxicity.
Conclusion
There is now a wealth of evidence linking aspirin intake to
a reduction in breast cancer risk and this study clearly
adds the importance of oestrogen receptor status into the
debate. Understanding the mechanism of action of aspirin
draws emphasis to the importance of COX and
prostaglandins in the pathogenesis of breast cancer.
Indeed, the enzyme COX-2 is upregulated in human
breast cancers [6] and administration of COX-1 and
COX-2 inhibitors to mice with established tumours leads
to inhibition of tumour growth and a decrease in meta-
static capacity [7]. Similarly, administration of NSAIDS to
rats with induced mammary carcinogenesis led to a
decrease in tumour volume and reduced gene expression
of COX-1 and COX-2 [reviewed in 8]. Information
regarding aspirin dose is still lacking and several studies
have suggested that a high dose (>100 mg/day) will be
necessary [1], which will naturally increase the risk of
common adverse effects of NSAIDS, including peptic
ulcer disease and gastrointestinal bleeding. Further
research into this subject is still necessary; however,
aspirin appears to hold an important protective role.
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